SCHEMBL6099760

SCHEMBL6099760

COCCN1CCC(C(=O)OC)(S(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 11/20 0.48
MMP2 P08253 10/20 0.48
MMP14 P50281 5/20 0.45
MMP9 P14780 5/20 0.45
MMP3 P08254 4/20 0.45
MMP8 P22894 4/20 0.45
MMP7 P09237 3/20 0.45
MMP12 P39900 1/20 0.45
FPR2 P25090 1/20 0.45
PROKR1 Q8TCW9 1/20 0.45
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
LIPE Q05469 1/20 0.41
ADRB2 P07550 1/20 0.41
MMP1 P03956 2/20 0.40
CACNA1G O43497 1/20 0.40
KCNH2 Q12809 1/20 0.40
TEAD1 P28347 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097338 0.92 MMP13 (0.47) MMP13MMP2MMP14MMP9MMP3
SCHEMBL6095377 0.91 MMP9 (0.54) MMP13MMP2MMP14MMP9MMP3
SCHEMBL6096560 0.91 MMP14 (0.56) MMP13MMP2MMP14MMP9MMP3
SCHEMBL6097858 0.86 ADRB2 (0.49) MMP13MMP2MMP9MMP12LIPE
SCHEMBL6099484 0.84 MMP13 (0.49) MMP13MMP2MMP14MMP9MMP3
SCHEMBL6095579 0.84 MMP13 (0.41) MMP13MMP2MMP14MMP9MMP3
SCHEMBL6096556 0.83 MMP14 (0.54) MMP13MMP2MMP14MMP9MMP3
SCHEMBL6098022 0.82 MMP14 (0.66) MMP13MMP2MMP14MMP9MMP3
Hydrochloric Acid SCHEMBL6402161 0.82 MMP14 (0.65) MMP13MMP2MMP14MMP9MMP3
SCHEMBL6097350 0.81 MMP13 (0.47) MMP13MMP2MMP14MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 US disclosed
US-6492367-B1 Sulfamato hydroxamic acid metalloprotease inhibitor G. D. SEARLE & COMPANY 2002-12-10 US disclosed
US-6448250-B1 INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 G. D. SEARLE & COMPANY 2002-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 MMP13 23/4885MMP2 8/4885MMP14 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.